Treatment Combo Shows 'Clinical Benefit' in Liver Cancer Trial

The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study.

Related Keywords

California ,United States ,Milan ,Lombardia ,Italy ,San Francisco ,Lorenza Rimassa ,Robin Kate Kelley ,University Of California ,Humanitas University ,Genentech ,Lancet Oncology ,Hepatocellular Carcinoma ,Liver Cancer ,Dcc ,Hepatocellular Cancer ,Ancer Liver ,Ancer Hepatocellular ,Biologic Therapy ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Renal Cell Carcinoma ,Ancer Kidney ,Ancer Renal Cell ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Neoplasm ,Tumor ,Gastrointestinal Hemorrhage ,Gastrointestinal Bleeding ,Bleedi ,